Search
Clinician Ordering Portal
Scientific Evidence
Improving patient selection for adjuvant therapy: considerations for the role of the 31-gene expression profile test
Oct 2022
Utilizing patient data provided through collaboration with the NCI SEER program in patients with Stage I-III CM, 31-GEP class result was a significant independent predistor of both MSS and OS. Patients with 31-GEP results in addition to clinicopathologic factors had improved survival.
Publication: Poster, presented at the Society for Melanoma Research Conference, Edinburgh Scotland, October 17-20 2022
Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test
Jul 2022
Validation of the integration the 31-GEP testing with clinpath features for invidialized risk assessment of MSS, DMFS, and RFS.
Publication: Journal of the American Academy of Dermatology
Incorporating the 31-gene expression profile test stratifies survival outcomes and leads to improved survival compared to clinicopathologic factors alone: a surveillance, epidemiology and end results (SEER) program collaboration
Apr 2022
Utilizing patient data provided through collaboration with the NCI SEER program in patients with Stage I-III CM, 31-GEP class result was a significant independent predistor of both MSS and OS. Patients with 31-GEP results in addition to clinicopathologic factors had improved survival.
Publication: Poster, presented at the 18th European Association of Dermato Oncology (EADO) Congress, Seville Spain, April 21-23 2022.
Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th edition staging
Apr 2022
DecisionDx-Melanoma data significantly stratified MSS in stage I, II, and III patients. This test has also demonstrated high specificity and NPV for melanoma-specific mortality (MSM).
Publication: Melanoma Research
Development and validation of a nomogram incorporating gene expression profiling and clinical factors for accurate prediction of metastasis in patients with cutaneous melanoma following MOHS micrographic surgery
Apr 2022
Prospective multicenter study showed that integration of 31-GEP and T stage can gain clinically useful prognostic information from data obtained noninvasively.
Publication: Journal of the American Academy of Dermatology
Expert consensus on the use of prognostic gene expression profiling tests for the management of cutaneous melanoma: consensus from the skin cancer prevention working group
Mar 2022
Expert panel of 8 dermatologists from the Skin Cancer Prevention Working Group developed 6 concensus statements supporting the appropriate use of GEP testing.
Publication: Dermatology and Therapy
Using a 31-gene expression profile test to stratify patients with stage I–II cutaneous melanoma according to recurrence risk: update to a prospective, multicenter study
Feb 2022
The 31-GEP accurately identified patients with stage IB-II CM at low and high risk of melanoma relapse in a prospective, multicenter study. Identifying which tumors have the highest probability of recurrence or metastasis, despite negative SLN results can aid in earlier disease detection.
Publication: Cancers
Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study
Feb 2022
Final report from a prospective study assessing the impacy of 31-GEP testing results on clinical management decisions including changes in imaging, laboratory work, and frequency of office visits. Outcomes data included.
Publication: Current Medical Research and Opinion
Attitudes of patients with cutaneous melanoma toward prognostic testing using the 31-gene expression profile test
Oct 2021
Patient survery performed in conjunction with Melanoma Research Foundation on patient attitudes towards prognostic testing
Publication: Cancer Medicine
The 31-gene expression profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma
Sep 2021
DecisionDx-Melanoma significantly stratified patient risk for RFS, DMFS, and MSS (p < 0.001) and was a significant, independent predictor of metastatic recurrence (hazard ratio: 5.38; p = 0.014).
Publication: Future Oncology
Integrating 31-Gene expression profiling with clinicopathologic features to optimize cutaneous melanoma sentinel lymph node metastasis prediction
Sep 2021
Validation of integrated 31-GEP (i31-GEP) neural network algorithm incorporating clinicopathologic factors with the continuous 31-GEP score for personalized SLNB positivity risk assessment.
Publication: JCO Precision Oncology
Long-term outcomes in a multicenter, prospective cohort evaluating the prognostic 31-gene expression profile for cutaneous melanoma
Apr 2021
Prospective analysis reporting long-term outcomes for patients tested with DecisionDx-Melanoma (follow-up to study first published as Hsueh, 2017).
Publication: JCO Precision Oncology